Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes

Sun H Kim, Fahim Abbasi, Cindy Lamendola, Alice Liu, Danit Ariel, Patricia Schaaf, Kaylene Grove, Vanessa Tomasso, Hector Ochoa, Yeheng V Liu, Yii-Der Ida Chen, Gerald Reaven, Sun H Kim, Fahim Abbasi, Cindy Lamendola, Alice Liu, Danit Ariel, Patricia Schaaf, Kaylene Grove, Vanessa Tomasso, Hector Ochoa, Yeheng V Liu, Yii-Der Ida Chen, Gerald Reaven

Abstract

Objective: The aim was to evaluate the ability of liraglutide to augment weight loss and improve insulin resistance, cardiovascular disease (CVD) risk factors, and inflammation in a high-risk population for type 2 diabetes (T2DM) and CVD.

Research design and methods: We randomized 68 older individuals (mean age, 58±8 years) with overweight/obesity and prediabetes to this double-blind study of liraglutide 1.8 mg versus placebo for 14 weeks. All subjects were advised to decrease calorie intake by 500 kcal/day. Peripheral insulin resistance was quantified by measuring the steady-state plasma glucose (SSPG) concentration during the insulin suppression test. Traditional CVD risk factors and inflammatory markers also were assessed.

Results: Eleven out of 35 individuals (31%) assigned to liraglutide discontinued the study compared with 6 out of 33 (18%) assigned to placebo (P=0.26). Subjects who continued to use liraglutide (n=24) lost twice as much weight as those using placebo (n=27; 6.8 vs. 3.3 kg; P<0.001). Liraglutide-treated subjects also had a significant improvement in SSPG concentration (-3.2 vs. 0.2 mmol/L; P<0.001) and significantly (P≤0.04) greater lowering of systolic blood pressure (-8.1 vs. -2.6 mmHg), fasting glucose (-0.5 vs. 0 mmol/L), and triglyceride (-0.4 vs. -0.1 mmol/L) concentration. Inflammatory markers did not differ between the two groups, but pulse increased after liraglutide treatment (6.4 vs. -0.9 bpm; P=0.001).

Conclusions: The addition of liraglutide to calorie restriction significantly augmented weight loss and improved insulin resistance, systolic blood pressure, glucose, and triglyceride concentration in this population at high risk for development of T2DM and CVD.

Trial registration: ClinicalTrials.gov NCT01784965.

Figures

Figure 1
Figure 1
Proportion of individuals who lost at least 5, 7, and 10% of baseline weight. Liraglutide treatment was associated with greater degree of weight loss compared with placebo.
Figure 2
Figure 2
Insulin resistance (SSPG) at baseline and after 14 weeks of liraglutide or placebo treatment. Insulin resistance significantly improved following liraglutide treatment but not placebo.

References

    1. Kim SH, Chunawala L, Linde R, Reaven GM. Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose: impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a community-based medical practice. J Am Coll Cardiol 2006;48:293–297
    1. Karve A, Hayward RA. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults. Diabetes Care 2010;33:2355–2359
    1. Association AD, American Diabetes Association Standards of medical care in diabetes—2013. Diabetes Care 2013;36(Suppl. 1):S11–S66
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    1. Tuomilehto J, Lindström J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350
    1. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544
    1. Saito T, Watanabe M, Nishida J, et al. Zensharen Study for Prevention of Lifestyle Diseases Group Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med 2011;171:1352–1360
    1. Heshka S, Anderson JW, Atkinson RL, et al. Weight loss with self-help compared with a structured commercial program: a randomized trial. JAMA 2003;289:1792–1798
    1. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771.
    1. Astrup A, Rössner S, Van Gaal L, et al. NN8022-1807 Study Group Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606–1616
    1. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33:1173–1175
    1. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:2670–2678
    1. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 1981;30:387–392
    1. Knowles JW, Assimes TL, Tsao PS, et al. Measurement of insulin-mediated glucose uptake: Direct comparison of the modified insulin suppression test and the euglycemic, hyperinsulinemic clamp. Metabolism 2013;62:548–553
    1. U.S. Department of Health and Human Services PHS NHANES III anthropometric procedures video. Washington, DC, U.S. Government Printing Office, 1996
    1. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association. National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752
    1. McLaughlin T, Carter S, Lamendola C, et al. Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults. Am J Clin Nutr 2006;84:813–821
    1. Orskov L, Holst JJ, Møller J, et al. GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia 1996;39:1227–1232
    1. McLaughlin T, Abbasi F, Kim HS, Lamendola C, Schaaf P, Reaven G. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women. Metabolism 2001;50:795–800
    1. Holst JJ, Toft-Nielsen MB, Orskov C, Nauck M, Willms B. On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects. Ann N Y Acad Sci 1996;805:729–736
    1. Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF, Diabetes Prevention Program Research Group Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 2009;32:1583–1588
    1. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, Diabetes Prevention Program Research Group Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243–2251
    1. Marre M, Shaw J, Brändle M, et al. LEAD-1 SU study group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268–278
    1. Zinman B, Gerich J, Buse JB, et al. LEAD-4 Study Investigators Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224–1230
    1. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234–2243
    1. Griffioen KJ, Wan R, Okun E, et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res 2011;89:72–78
    1. Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 2013;15:42–54

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅